

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/247900 A1

(51) International Patent Classification:

A61K 31/5375 (2006.01) A61K 9/00 (2006.01)
A61K 31/4412 (2006.01)

(21) International Application Number:

PCT/US2021/035749

(22) International Filing Date:

03 June 2021 (03.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2020901856 05 June 2020 (05.06.2020) AU
2020901858 05 June 2020 (05.06.2020) AU

(71) Applicant: **OCCURX PTY. LTD.** [AU/AU]; Level 9, 31 Queen Street, Melbourne, Victoria 3000 (AU).

(71) Applicant (for GH only): **JOSEPH M. REISMAN** [US/US]; 2040 Main Street, 14th Floor, Irvine, California 92614 (US).

(72) Inventors: **KELLY, Darren**; Level 9, 31 Queen Street, Melbourne, Victoria 3000 (AU). **PAPADIMITRIOU, Michelle**; Level 9, 31 Queen Street, Melbourne, Victoria 3000 (AU). **BURNS, Chris**; Level 9, 31 Queen Street, Mel-

bourne, Victoria 3000 (AU). **DANIELS, Eric**; Level 9, 31 Queen Street, Melbourne, Victoria 3000 (AU).

(74) Agent: **DELANEY, Karoline**; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS





FIG. 1

(57) Abstract: Disclosed herein are methods of administration of (E)-2-[[3-methoxy-4-(difluoromethoxy)phenyl]-1-oxo-2-propenyl]amino]benzoic acid to a subject, involving particular administration regimes for preventing, treating, reducing the severity of and/or reducing the likelihood of reoccurrence of eye conditions such as diabetic retinopathy and proliferative vitreoretinopathy. Such eye conditions can have serious consequences, including loss of vision and, in some cases blindness.

WO 2021/247900 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*